How Will the Market React to Agenus Inc (AGEN) Stock Getting a Neutral Rating

Agenus Inc (AGEN) stock is higher by 13.24% over the past week and gets a Neutral rating from InvestorsObserver Sentiment Indicator.

Agenus Inc has a Neutral sentiment reading. Find out what this means for you and get the rest of the rankings on AGEN!

See Full AGEN Report

What is Stock Sentiment?

Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends. Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down. InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend. Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.

What's Happening With AGEN Stock Today?

Agenus Inc (AGEN) stock has gained 9.92% while the S&P 500 is down -0.12% as of 1:53 PM on Thursday, Nov 30. AGEN is up $0.07 from the previous closing price of $0.70 on volume of 5,402,811 shares. Over the past year the S&P 500 is higher by 14.84% while AGEN is down -70.16%. AGEN lost -$0.81 per share in the over the last 12 months. To see InvestorsObserver's Sentiment Score for Agenus Inc click here.

More About Agenus Inc

Agenus Inc is an American biotechnology company. Its main target is immuno-oncology treatments. The company's portfolio consists of therapeutic antibodies and vaccines to treat immuno-oncology illnesses: cancers, shingles, malaria, glioblastoma, and others. Agenus treatments aim, by combining multiple antibody platforms, to stimulate the immune system to recognize and fight cancer cells. The company has been cooperating with companies like Incyte, Merck Sharpe & Dohme, and Recepta Biopharma to achieve over a dozen antibody programs. Some of its products include Prophage, AutoSynVax, QS-21 Stimulon, and others. Click Here to get the full Stock Report for Agenus Inc stock.